Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine (Q34787766)

4 August 2017

1 reference

title

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine (English)

1 reference

4 August 2017

1 reference

Hans G Kress

1

1 reference

4 August 2017

24 June 2008

1 reference

4 August 2017

European Journal of Pain

1 reference

4 August 2017

13

1 reference

4 August 2017

3

1 reference

4 August 2017

219-230

1 reference

Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

21 January 2018

Buprenorphine kinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Pharmacokinetics of the combination tablet of buprenorphine and naloxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Intravenous buprenorphine self-administration by detoxified heroin abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine induces ceiling in respiratory depression but not in analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine in cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Reversibility of opioid receptor occupancy of buprenorphine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Should we be reluctant to prescribe opioids for chronic non-malignant pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

21 January 2018

Controlling cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine: a review of its pharmacological properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine: considerations for pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Deaths involving buprenorphine: a compendium of French cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Challenging the equipotency calculation for transdermal buprenorphine: four case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Some new insights into the effects of opioids in phasic and tonic nociceptive tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine suppresses heroin use by heroin addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Bioavailability of sublingual buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Age-dependent changes of the kidneys: pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Buprenorphine in long-term control of chronic pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Pharmacokinetics of opioids in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Inhibition of human drug metabolizing cytochrome P450 by buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Fracture risk associated with the use of morphine and opiates

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Clinical pharmacology of buprenorphine: ceiling effects at high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2008.04.011

10.1016/J.EJPAIN.2008.04.011

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

18567516